Peptide Tools to Study EBV

Epstein–Barr virus (EBV or Human gammaherpesvirus 4) is one of the most common viruses in humans. EBV causes infectious mononucleosis but is also associated with various lymphoproliferative diseases, malignancies and conditions associated with HIV as well as some childhood disorders and an elevated risk of developing certain autoimmune diseases. About 200,000 cancer cases per year are  attributed to EBV and studies suggest that EBV as the leading cause of multiple sclerosis.

About EBV (Epstein-Barr Virus)

Epstein-Barr virus  belongs to the family of Herpesviridae. It is known as the cause of infectious mononucleosis and infects immune and epithelial cells. Being able to establish a long-term, latent infection in human memory B cells, it is prevalent in the adult population (worldwide 90%).
The double standed virus DNA is protected by an icosahedral nucleocapsid, which is surrounded by a protein tegument and an envelope of glycoproteins and lipids.

EBV is associated with a range of human diseases and cancers

  • Hodgkin’s and Burkitt’s lymphoma, hemophagocytic lymphohistiocytosis
  • Nasopharyngal and gastric carcinoma
  • Main cause of post-transplant lymphoproliferative disease (PTLD) in immune suppressed transplant patients
  • Increases the risk of certain autoimmune diseases, e.g. lupus erythematosus, rheumatoid arthritis and multiple sclerosis
  • Plays a role in the development of chronic fatigue syndrome (CFS)
  • HIV associated diseases (hairy leukoplakia, central nervous system lymphomas)
  • Alice in Wonderland syndrome and acute cerebellar ataxia in children

The latent EBV Antigens

During latent infection EBV expresses only a small number of viral genes. Three major types of latency can be differentiated by their distinct expression patterns of these genes and are associated with the various types of diseases and cancer. Both, humoral and cellular (mainly CTL) immune responses play a role in controlling the primary and the latent phases of EBV infection.
Depending on the latency (I -III) program EBV expresses a subset of these proteins: EBNA-1, EBNA-2, EBNA-3A,EBNA-3B, EBNA-3C, EBNA-LP, LMP-1, LMP-2A, LMP-2B and EBER.

JPT's Peptide Tools to Study EBV (Epstein-Barr Virus)

Cellular Immune Response Profiling

-> PepMix™ Peptide Pools 
  • Antigen specific stimulation of T-cells
  • Immune monitoring of high-risk patients
  • Qualification of immunodominant antigens
  • Validating clinical T-cell assays
PepMix™ Collection EBV
Peptide pools of 13 immunodominant antigens in one plate for fast and economic immune response profiling.
EBV PepMix™ Peptide Pools
Peptide pools for single immunodominant antigens:
Tailored PepMix™ Peptide Pools for your specific needs!

  • T-cell assays in
  • High-throughput T-cell epitope discovery
  • Monitoring of cellular immune response
  • Clinical trials

We are the experts for peptide synthesis with highest quality optimized for many applications. Our peptide synthesis service has a very high success rate (over 99%) as we optimize the appropriate peptide synthesis method for each peptide.
If you would like to order a quality peptide synthesis using regulated processes, choose JPT!

Humoral Immune Response Profiling

-> EBV PepStar Peptide Microarrays 
Ready-made peptide microarrays displaying overlapping peptides through single immunodominant antigens: BARF1, BMLF1, BMRF1, BRLF1, BZLF1, EBNA-LP, EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, LMP1, LMP2, GP350/340.
  • Immune monitoring of humoral responses
  • Profiling of EBV specific samples or antibodies
  • Evaluation of co-infection
  • Detection of epitopes and epitope spreading

PepStar™ Antigen Collection
Combines overlapping peptides for all the proteins above on one microarray for optimal coverage of the most important antigens in a single experiment.
You define content and layout, we provide economic and fast production in our regulated clean-room environment. We also offer our assay and analysis service using your samples with your tailored peptide microarray.

Our tailored Peptide ELISA plates are offered as stand alone service for mapping of epitopes and definition of protein interaction sites or as validation assay to confirm results obtained with JPT’s peptide microarrays.

Clinical Peptides

-> Clinical Peptides
JPT’s Clinical Peptides product lines Clinical Grade and ISO Plus are produced in production environments that are regulated by an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy as well as vaccine and drug development. Depending on the specifics of the immunotherapy concept to be applied, the resulting products have been shown to be applicable in clinical applications.



  • A Co-stimulatory CAR Improves TCR-based Cancer Immunotherapy
    Omer et al., Cancer Immunology Research (2022) - PMID: 35176142
    Products used: PepMix EBV (EBNA1)EBV (LMP1), and EBV (LMP2)
  • A Lymph Node Targeted Adjuvant and Engineered Subunit Vaccine Promotes Potent Immunity to Epstein-Barr Virus in HLA-expressing Mice
    Dasari et al., Research Square (2022)
    Product used: PepMix EBV (GP350/GP340)
  • Rapid single-cell identification of Epstein Barr virus-specific T-cell receptors for cellular therapy
    Cobo et al., Cytotherapy (2022) - PMID: 35525797
  • Evaluation of IL-1β and IL-6 expression following EBNA-1 and BRLF-1 peptide treatment in Epstein Barr virus-positive multiple sclerosis patients
    Kianfar et al., Intervirology (2022)
  • Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay
    Cassaniti et al, Journal of Immunology Research (2019)
  • Measurement of CD8.sup.+ and CD4.sup.+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs
    Dae-Hee Sohn et al, PLoS ONE (2019)
  • T-Cell Responses Targeting HIV Nef Uniquely Correlate With Infected Cell Frequencies After Long-Term Antiretroviral Therapy
    Thomas et al, PLoS Pathogens (2019)
  • PRAME Peptide‐Specific CD8+ T Cells Represent the Predominant Response Against Leukemia‐Associated Antigens (LAAs) in Healthy Individuals
    Matko et al, European Journal of Immunology (2018)
  • Dynamics of Virus‐Specific T Cell Immunity in Pediatric Liver Transplant Recipients
    Arasaratnam et al, American Journal of Transplantation (2018)
  • Epstein-Barr Virus (EBV)-derived BARF1 Encodes CD4-and CD8-restricted Epitopes as Targets for T-cell Immunotherapy
    Kalra et al, Cytotherapy (2018)
  • Investigation of IL-2 and IFN-γ to EBV Peptides in Stimulated Whole Blood among Multiple Sclerosis Patients and Healthy Individuals
    Nastaran Raficc et al., Intervirology, (2021)
  • Human Cytomegalovirus and Epstein-Barr Virus Specific Immunity in Patients With Ulcerative Colitis
    Rachele Ciccocioppo et al., Clinical and Experimental Medicine, (2021)
  • Epstein-Barr Virus Antibodies And Uses Thereof
    Ogembo et al., United States Patent Application 20200055924 (2020) - PMID: n.a.


"My group is developing therapeutic strategies for using in vitro expanded virus-specific T cells (VSTs) for the treatment of viral infections in immunocompromised patients. We recently demonstrated the feasibility and clinical benefit associated with the infusion of rapidly generated single-culture VSTs, manufactured using JPT's GxP PepMix™ peptide pools covering 12 immunogenic antigens from five viruses (EBV, AdV, CMV, BK, and HHV6). When administered to 11 allogeneic stem cell transplant recipients, 8 of whom had up to four active infections, these VSTs produced an overall 94% response rate."
Ann Leen, PhD, Baylor College of Medicine, Houston, TX, USA

"The main focus of my research group at the Charité in Berlin is the development of novel immunotherapeutic approaches against cancer and infectious diseases. For reliable monitoring of tumor and virus specific T-cell responses we have a permanent need for peptides and peptide pools that are produced in a regulated environment for application in a clinical environment. JPT has been a long term and dedicated partner in this regard which continuously works on improving it's peptide based services."
Prof. Dr. Carmen Scheibenbogen, Charité Berlin, Germany

Application Notes

Check our list of products, click and go.

Get a quote